Analysts Set Maplight Therapeutics, Inc. (NASDAQ:MPLT) Target Price at $31.00

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $31.00.

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price target on the stock. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Leerink Partners started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “outperform” rating and a $30.00 target price on the stock. Jefferies Financial Group initiated coverage on Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $32.00 price target on the stock. Finally, Morgan Stanley assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 price target for the company.

Maplight Therapeutics Stock Performance

NASDAQ:MPLT opened at $18.51 on Monday. Maplight Therapeutics has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The stock has a market capitalization of $839.80 million and a price-to-earnings ratio of -0.50. The company’s 50 day moving average is $17.65.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) EPS for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Insider Activity

In other Maplight Therapeutics news, Director Timothy John Garnett bought 14,124 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was bought at an average price of $17.89 per share, for a total transaction of $252,678.36. Following the completion of the acquisition, the director directly owned 14,124 shares in the company, valued at $252,678.36. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert C. Malenka sold 21,262 shares of the firm’s stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $18.55, for a total value of $394,410.10. Following the completion of the sale, the director directly owned 371,885 shares of the company’s stock, valued at $6,898,466.75. The trade was a 5.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have acquired 39,124 shares of company stock valued at $693,846 and have sold 74,612 shares valued at $1,368,065.

Institutional Investors Weigh In On Maplight Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MPLT. Walleye Capital LLC bought a new position in Maplight Therapeutics in the fourth quarter worth about $205,000. MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics in the fourth quarter worth about $172,000. New York State Common Retirement Fund bought a new stake in Maplight Therapeutics during the 4th quarter valued at approximately $93,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $70,000. Finally, 5AM Venture Management LLC purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.